Quantcast

Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia

Roche is also close to completing enrolment of a global randomised, double-blind, placebo-controlled phase III clinical trial of Actemra®/RoActemra® (tocilizumab) in hospitalised patients with severe COVID-19 pneumonia (COVACTA), with results expected this summer.

Read more

Roche testing with BARDA Actemra’s potential utility in severe COVID-19 pneumonia patients. Working on availability of COVID 19-tests.

Roche said Tuesday it started testing Actemra (tocilizumab) with the Biomedical Advanced Research and Development Authority (BARDA)on top of standard of care in hospitalised adult patients with severe COVID-19 pneumonia compared to placebo on top of standard of care.

Read more